effera®

helaina™

Lactoferrin in Women's Health

Mechanisms and Evidence Across the Adult Female Lifespan

A Clinical and Mechanistic Review, Including effera® Human Lactoferrin

1. Executive Summary

Lactoferrin (LF) is an 80 kDa multifunctional iron-binding glycoprotein present in human colostrum, mature milk, saliva, tears, gastrointestinal secretions, and the female reproductive tract[1]. Its relevance to women's health extends well beyond any single hormonal window: Rather, LF's mechanisms of action operate continuously across the female lifespan and across multiple body systems. This review is organized into three sections. First, we describe the structural distinction between bovine-derived lactoferrin (bLF), the ingredient historically used in most commercial formulations, and **effera®**, a human-identical lactoferrin produced through precision fermentation. Second, we examine the four core mechanisms of action that consistently emerge throughout the literature: iron regulation, microbiome modulation, immune and inflammatory regulation, and cellular health. Third, we review the evidence by life stage (adolescence, fertility, pregnancy, menopause) and by body system (immune, gut, vaginal, iron status, hair, skin, bone, athletic performance, metabolic health).

Every mechanistic and clinical claim in this document is attributed to a specific peer-reviewed source. Where findings are proprietary to **effera®** and have not yet been published in a peer-reviewed journal, this is stated explicitly, including their current publication status.

2. The "Scientific Why": Understanding Lactoferrin

Lactoferrin is a glycosylated,iron-binding member of the transferrin family that is present in especially high concentrations in colostrum and declines over the course of lactation[2]. It can chelate two ferric (Fe^{3+}) ions per molecule with an affinity hundreds of times greater than transferrin, and uniquely retains this iron-binding capacity at acidic pH levels as low as 3.0, which are typical of inflamed tissue[3].

Structurally, LF consists of a polypeptide chain organized into two globular lobes connected by an α-helix, each containing two domains arranged as β-sheets. This structure underlies its classification as a hybrid, multifunctional protein[2].

3. effera®: From a ~70% Structural Match to Human-Identical

Most of the foundational lactoferrin literature, including many of the studies cited throughout this review, was generated using bovine lactoferrin (bLF), as it was historically the only commercially available source. However, the recent commercialization of **effera®**, a bioidentical human lactoferrin, now enables direct evaluation of the human protein. Understanding where bLF and human lactoferrin (hLF) converge and diverge structurally is central to interpreting this evidence base and understanding what **effera®**, a precision-fermented, human-identical lactoferrin, adds to it.

3.1 Amino Acid Sequence Homology Across Species

Using global pairwise alignment (Needleman-Wunsch) of UniProt reference sequences against human lactoferrin (Homo sapiens, UniProt P02788), bovine lactoferrin (Bos taurus) shows approximately 69.7% sequence identity to human LF. This represents roughly a 30% amino acid difference, making it the most structurally distant of the commonly available mammalian sources evaluated. Comparable non-primate species show similar levels of sequence identity: goat (Capra hircus) ~70.8%, pig (Sus scrofa) ~70.7%, camel (Camelus dromedarius) ~74.1%, and horse (Equus caballus) ~73.4%, whereas chimpanzee shares 97.6% sequence identity[4]. Independent literature estimates place bovine sequence identity at approximately 69%, with minor variation across analyses attributable to alignment methodology and reference sequence version[5] [6] [7] [8].

3.2 What the Structural Gap Means Functionally

This is not a minor difference. Lactoferrin's physiological effects depend on receptor-mediated interactions, including the lactoferrin receptor (LfR) on intestinal brush-border cells, LRP1 on keratinocytes and dermal fibroblasts, and immune cell surface receptors. Its activity also depends on glycosylation patterns that differ between bovine and human LF. Consistent with these structural differences, direct comparison studies have shown that human lactoferrin stimulates greater growth of *Bifidobacterium* species, including *B. infantis*, than bovine lactoferrin. These studies also demonstrate that bioactivity differences between talactoferrin (recombinant human LF) and bovine and human milk LF are measurable in head-to-head assays[9] [10].

3.3 effera®: A Human-Identical Alternative

effera® is produced via precision fermentation using *Komagataella phaffii* and is the first commercially available lactoferrin with a primary amino acid sequence that exactly matches native human lactoferrin. In digestive-stability comparisons, **effera®** retained substantially more intact protein through simulated gastric and intestinal digestion than bovine lactoferrin, behaving similarly to human milk lactoferrin[11]. **effera®** is structurally identical to endogenous human lactoferrin, enabling receptor interactions that mirror those of the native protein. As a result, it binds the human lactoferrin receptor (LfR) on the intestinal brush border more efficiently than bovine lactoferrin[12].

3.4 Immune Recognition and Tolerability

A workshop-reviewed safety roadmap for recombinant human lactoferrin evaluated immunogenicity, immunotoxicology, iron homeostasis, and digestion to provide a robust framework for establishing food-ingredient safety[13]. An allergenicity risk assessment, benchmarked against Codex Alimentarius guidelines and comparing **effera®**'s amino acid sequence and glycan structures with known allergens, found no evidence of allergenic risk[14]. In a separate randomized, double-blind, controlled trial that assessed immunological and safety parameters in healthy adults receiving two **effera®** doses versus an active control, **effera®** did not induce anti-lactoferrin antibody formation, a response that has been observed with bovine lactoferrin[15].

4. The Core Four Mechanisms of Action

Four interconnected mechanisms recur throughout the lactoferrin literature and underlie its relevance across women's health applications. They are introduced here and serve as the foundation for the sections that follow.



4.1 Iron Regulation & Hepcidin Biology

Iron homeostasis is the mechanism from which much of lactoferrin's biology flows[2]. Inflammation elevates interleukin-6 (IL-6), which stimulates hepatic hepcidin synthesis. Hepcidin then binds and degrades ferroportin, the cellular iron exporter, trapping iron inside enterocytes, macrophages, and hepatocytes regardless of dietary intake[16]. This is the pathophysiology of anemia of chronic inflammation, which contributes to an estimated 40% of anemia cases worldwide[17]. Lactoferrin lowers circulating IL-6, thereby reducing hepcidin and restoring ferroportin-mediated iron export. It also independently activates the Nrf2 transcription factor to upregulate ferroportin gene expression, providing a dual, cytokine-mediated and transcriptional mechanism not replicated by conventional iron salts[18].

These mechanistic effects translate into clinically meaningful improvements in iron status. Multiple independent randomized controlled trials demonstrate that lactoferrin outperforms ferrous sulfate on iron biomarkers with markedly better tolerability[19] [20] [21]. In addition, **effera®**'s human-identical structure gives it native-affinity binding to the human LfR receptor, and direct absorption of iron from recombinant human lactoferrin has been demonstrated in young women[12].

4.2 Microbiome & Microbial Control

Lactoferrin's primary microbiological mechanism is iron sequestration: chelating free luminal ferric iron creates an iron-restricted environment that limits iron-dependent pathogenic bacteria while sparing iron-independent commensals such as *Bifidobacterium* and *Lactobacillus*[22]. Enzymatic digestion of lactoferrin also releaseslactoferricin, an antimicrobial peptide that disrupts bacterial membranes and inhibits biofilm formation[23]. In a 28-day randomized, double-blind trial of 66 healthy adults, **effera®** at two doses significantly increased beneficial gut taxa, including *Faecalibacterium, Lachnospira,* and *Paraprevotella*, relative to bovine lactoferrin[24]. These findings are consistent with earlier comparative work showing human lactoferrin's greater bifidogenic specificity relative to bovine LF[9].

4.3 Immune Regulation & Inflammatory Signaling

Lactoferrin functions as a bidirectional immune calibrator, supporting immune readiness when pathogen burden is low while suppressing excessive inflammatory signaling under chronic or dysregulated conditions[25]. This primary anti-inflammatory mechanism operates through NF-κB. Lactoferrin binds lipopolysaccharide (LPS) and interferes with TLR2, TLR4, and TLR9 signaling via CD14, limiting downstream transcription of IL-6, TNF-α, and IL-1β[26]. These immunomodulatory effects have been demonstrated in clinical studies. A systematic review and meta-analysis of lactoferrin supplementation found measurable reductions in inflammation and infection risk[27]. More recently, a 2026 randomized controlled trial in healthy older adults showed that oral lactoferrin reduces systemic inflammation, enhances antiviral responses, and modulates immune cell profiles[28].

4.4 Cell Health: Gene Expression & Tissue Regeneration

Lactoferrin's least widely recognized capability is its direct influence on cellular biology, including gene expression, stem cell production, and tissue regeneration, particularly relevant to skin, hair, and bone applications[29]. Apo-lactoferrin chelates iron and inhibits prolyl-hydroxylase domain (PHD) enzymes that normally degrade HIF-1α under normoxic conditions. This stabilizes HIF-1α, mimicking a physiological hypoxic state that activates VEGF transcription, neovascularization, and collagen and elastin production[30].Lactoferrin also binds LRP1 receptors on keratinocytes and dermal papilla cells, activating Wnt/β-catenin, MAPK/ERK, and PI3K/Akt growth signaling. In addition, it reduces intracellular ROS and caspase-3 activation in mesenchymal stem cells, limiting oxidative stress-induced senescence and apoptosis[31].

5. Lactoferrin Across the Female Lifespan

Estrogen directly regulates lactoferrin gene expression via estrogen response elements, which is why much of the clinical literature is organized around hormonal life stages[32]. However, this is only one lens through which lactoferrin can be understood; Section 6 covers systems that are not primarily hormone-driven.

5.1 Adolescence and Menstrual Health

Lactoferrin is produced by uterine epithelial cells and is present in both the endometrium and vaginal epithelium. Its gene expression rises during the estrogen-dominant follicular phase and falls during the progesterone-dominant luteal phase[32]. Menstrual blood loss, combined with the increased iron demands of adolescent growth, elevates the risk of iron deficiency anemia during adolescence[17].

PMS-related cramping is driven by prostaglandins E2 and F2α, which are amplified by NF-κB-mediated inflammatory signaling. Lactoferrin suppresses NF-κB via TLR4/CD14 interference and inhibits COX-2 activity, a key enzyme in prostaglandin synthesis[33]. Consistent with these mechanisms, a double-blind, randomized, placebo-controlled crossover study found that women receiving an iron-lactoferrin complex had significantly improved Menstrual Distress Questionnaire scores and heart rate variability compared with placebo, consistent with reduced PMS-related autonomic and psychological symptoms[34].

5.2 Fertility and Preconception

Lactoferrin is active at every principal stage of fertility: ovulation, sperm-egg interaction, implantation, and early embryonic development, across both female and male reproductive systems. LF levels rise during the follicular phase and peak around ovulation. It is also present at the site of sperm-egg interaction in the oviduct, where it binds to sperm during capacitation. Iron is required for the rapid cell division underlying follicular development and oocyte maturation. However, elevated reactive oxygen species in follicular fluid, whether from iron deficiency or iron excess, are among the best-documented markers of poor oocyte quality[2].

Fertility also depends on tightly regulated inflammation. Ovulation and implantation require transient, controlled inflammatory signaling, while sustained implantation requires immune tolerance toward the genetically distinct embryo. Lactoferrin influences macrophage, natural killer cell, and antigen-presenting cell activity to support this balance[18]. Higher lactoferrin levels in follicular fluid have been associated with improved fertilization and embryo quality[35]. In addition, a *Lactobacillus*-dominant uterine and vaginal microbiome, which lactoferrin supports through iron restriction of competing pathogens, is associated with significantly higher implantation and live birth rates in IVF studies[36].

5.3 Pregnancy, Prenatal and Postnatal Health

Ferrous sulfate, the conventional iron supplement used during pregnancy, is poorly absorbed (10–30% bioavailability), generates free luminal iron that induces oxidative stress, and carries a 25–30% discontinuation rate due to gastrointestinal side effects. Importantly, it does not address the inflammation-driven hepcidin elevation that is the dominant mechanism of iron restriction in late pregnancy[37].

Multiple independent randomized controlled trials in pregnant women demonstrate that lactoferrin produces significantly superior improvements in hemoglobin, serum iron, and transferrin saturation than ferrous sulfate, despite providing a fraction of the elemental iron dose and causing markedly fewer adverse events[38] [39] [40]. These findings were confirmed across trials in a 2022 meta-analysis[21].

Postpartum, blood loss at delivery combined with lactation demands results in substantial iron depletion in an estimated 20–50% of women. At the same time, inflammation from delivery elevates IL-6 and hepcidin precisely when the recovering body needs iron most[16].

Lactation redirects calcium from maternal bone to breast milk, producing a 3–10% loss in bone mineral density. Lactoferrin is characterized in the peer-reviewed literature as a bone growth factor, stimulating osteoblast proliferation and differentiation to levels 3–5 times above controls and reducing osteoblast apoptosis by 50–70% in vitro[41] [42].

5.4 Perimenopause and Menopause

Estrogen suppresses hepcidin production via an estrogen response element in the hepcidin promoter. As estrogen declines at menopause, hepcidin rises, driving both iron sequestration and, paradoxically, pro-oxidant free-iron accumulation as serum ferritin rises 2–3-fold post-menopause[43]. Lower estrogen also increases pro-inflammatory cytokines and decreases endogenous LF production. Because inflammatory cytokines impair osteoclast regulation, these changes contribute directly to postmenopausal bone loss[41].

In a 6-month randomized controlled trial in postmenopausal women, ribonuclease-enriched lactoferrin (250 mg/day) combined with calcium significantly reduced the bone-resorption marker urinary deoxypyridinoline while increasing bone-formation markers (including bone-specific alkaline phosphatase and osteocalcin) [44]. A companion analysis of the same cohort found significant reductions in IL-6, TNF-α, and C-reactive protein along with increases in the anti-inflammatory cytokine IL-10, demonstrating a mechanistic link between LF's anti-inflammatory and bone-protective effects in this population [45. Lactoferrin activates LRP1-, MAPK-, PI3K/Akt-, and RANKL/OPG-mediated signaling, thereby promoting osteoblast activity and inhibiting osteoclast-mediated bone resorption, a mechanism reviewed comprehensively in a 2025 synthesis of preclinical and clinical evidence[46].

Beyond its effects on bone, declining estrogen reduces vaginal epithelial glycogen, leading to a loss of Lactobacillus dominance and an increase in vaginal pH. Together, these changes increase susceptibility to bacterial vaginosis, vulvovaginal candidiasis, urinary tract infection, and atrophic vaginitis, conditions that affect an estimated 60% of postmenopausal women. In postmenopausal women, a combination of tibolone, Lactobacillus, and lactoferrin (50 mg) produced measurable improvements in vulvar pain, genital comfort, and lubrication after 90 days[47].

6. Lactoferrin Across Body Systems

The applications below are not limited to a single hormonal life stage. Instead, they represent body systems in which lactoferrin's Core Four mechanisms (Section 4) are directly relevant to women's health, regardless of reproductive status.

6.1 Immune Function and Antiviral Defense

Lactoferrin binds heparan sulfate proteoglycans (HSPGs), cell-surface attachment sites exploited by influenza, RSV, herpes, HIV, and SARS-CoV-2 as docking sites prior to cell entry, thereby blocking viral attachment before infection begins [48]. In a randomized, double-blind, placebo-controlled trial, enteric-coated lactoferrin supplementation improved measures of immune function in elderly individuals[49]. Similarly, bovine lactoferrin has been shown to enhance TLR7-mediated plasmacytoid dendritic cell responses specifically in elderly women[50].

6.2 Gut Health and the Microbiome

The intestinal epithelial barrier depends on tight-junction proteins[51,68] (ZO-1, claudin-1, and occludin) to maintain a functional paracellular barrier. Lactoferrin enhances the expression of these proteins, restores transepithelial electrical resistance (TEER), and blocks caspase-3-mediated cleavage that compromises barrier integrity[51].

effera® × Cryptobiotix ex vivo gut model

To better understand how effera® behaves in the gut, it was evaluated using the advanced ex vivo human gut simulation platform SIFR® (Cryptobiotix, Ghent, Belgium). SIFR® recreates digestion, gut microbial fermentation, and interactions with the intestinal lining using fecal microbiota from six healthy human donors. Test arms included effera® at 50–1000 mg/day, bovine lactoferrin at 100–1000 mg/day, human lactoferrin at 1000 mg/day, skimmed milk, and a no-substrate control[52].

effera® increased production of beneficial short-chain fatty acids (SCFAs), beginning at the lowest dose tested (50 mg/day). It also increased transepithelial electrical resistance (TEER), a standard index of gut barrier strength, in a dose-dependent manner, with the effect most pronounced under inflammatory (LPS) challenge. In addition, effera® supported expression of the tight-junction proteins ZO-1 and occludin, reduced the inflammatory chemokine CXCL-10 below control levels at every dose tested, and increased beneficial microbial biomass in a dose-dependent manner. Across matched doses, effera® produced higher TEER than bovine lactoferrin at every dose tested. Notably, 50 mg of effera® exceeded the barrier-strengthening effect of both 100 mg and 500 mg of bovine lactoferrin[52].

NOTE ON DATA STATUS

This study was presented as a poster at the ISSN 2026 Annual Conference; the full peer-reviewed manuscript is in preparation. Findings above reflect only what was publicly presented at that conference; internal sales materials contain additional pre-publication detail and competitive framing that is not reflected here pending manuscript publication and regulatory review.

6.3 Vaginal and Reproductive Tract Health

Bacterial vaginosis (BV) affects an estimated 30–40% of reproductive-age women, with roughly 25% experiencing recurrence within four weeks of antibiotic treatment. Vulvovaginal candidiasis (VVC) affects approximately 75% of women at least once[36]. Multiple randomized trials demonstrate that lactoferrin-probiotic combinations significantly outperform placebo for BV treatment and recurrence prevention[53] [54] as well as recurrent VVC [55]. In a study of women with BV randomized to receive 100 mg or 200 mg vaginal lactoferrin pessaries for 10 days, both doses significantly increased Lactobacillus and reduced Gardnerella and Prevotella while restoring a healthier vaginal pH[56].

In Vitro Activity Against Gardnerella vaginalis (effera®-specific data)

In a controlled in vitro inhibitory-concentration assay (with n=6 replicates) measuring reduction of Gardnerella vaginalis (ATCC 14019) relative to an untreated growth control, **effera®** reduced the G. vaginalis population by approximately 87%, representing around 1.7 times the reduction achieved by bovine lactoferrin, the current commercial benchmark. A non-bioactive bovine serum albumin control confirmed assay validity[57]. These findings represent preliminary in vitro data characterizing activity in a controlled laboratory setting and do not reflect clinical outcomes.

6.4 Iron Status and Anemia Management

Iron deficiency without anemia (serum ferritin below approximately 30 µg/L with normal hemoglobin) produces fatigue, cognitive fog, reduced physical performance, and mood disturbance. This represents a substantially underserved population because iron salts are poorly tolerated by many individuals who have not yet progressed to anemia[58]. As detailed in Sections 4.1 and 5.3, lactoferrin's hepcidin-lowering mechanism differentiates it from iron salts in terms of both efficacy and gastrointestinal tolerability, a finding replicated in a 2024 systematic review and meta-analysis comparing oral bovine lactoferrin with iron supplementation[59].



6.5 Hair Health

Low ferritin is strongly associated with telogen effluvium, the most common form of diffuse hair shedding in women. Inflammation-driven hepcidin elevation can create functional iron deficiency in follicular cells even when total iron intake is adequate[29]. Lactoferrin activates ERK and Akt phosphorylation in dermal papilla cells, the master regulators of the hair cycle, and induces Wnt/β-catenin signaling essential for anagen (growth-phase) induction. Bovine lactoferrin has been shown to promote dermal papilla cell proliferation and hair growth in vivo through these pathways, while human lactoferrin specifically promotes keratinocyte proliferation and migration via LRP1/MAPK signaling[60] [30].

6.6 Skin Health

UV radiation, pollution, and inflammation increase oxidative stress in the skin. Under these conditions, mobilization of intracellular labile iron can amplify oxidative damage by driving Fenton reactions that generate highly reactive hydroxyl radicals, contributing to lipid peroxidation, DNA damage, and degradation of the extracellular matrix[29]. Recombinant human lactoferrin has been shown to stimulate keratinocyte proliferation and promote migration via LRP1/MAPK/Src/Rho pathways. It also improves wound healing in a swine burn model through an LRP1-dependent, structure-specific mechanism [30].

6.7 Musculoskeletal and Bone Health

This mechanism is introduced in the menopause context (Section 5.4) because estrogen decline and the accompanying increase in iron stores are the most extensively studied drivers in women. However, the downstream biology of iron-mediated oxidative damage is not unique to menopause and occurs across multiple physiological and pathological contexts. At physiological concentrations (1–100 µg/mL), lactoferrin induces dose-related increases in osteoblast-like cell proliferation and differentiation, reaching 3–5 times above controls. Its potency has also been reported to exceed that of several established growth factors, while simultaneously inhibiting osteoclastogenesis, with complete arrest at 100 µg/mL in mouse bone marrow cultures[41] [42]. This dual mechanism, stimulating bone formation while inhibiting resorption, is also directly relevant to the musculoskeletal risks of GLP-1 therapy (Section 6.9) and to athletic training load (Section 6.8), independent of menopausal status.

Iron supports musculoskeletal health through complementary effects on skeletal muscle and bone [69, 70]. In skeletal muscle, iron deficiency is associated with lower muscle mass and impairs myoblast proliferation, mitochondrial energy metabolism and myocyte integrity, even in the absence of anemia. In bone, iron deficiency contributes to low-turnover remodeling by limiting the energy production and iron-dependent enzymatic processes necessary for osteoblast function and collagen maturation.

6.8 Female Athletes

Female athletes have greater iron requirements than male athletes because of menstrual blood loss and exercise-related demands. These demands are compounded by the transient post-exercise rise in hepcidin, which can reduce iron absorption and availability, contributing to the substantially higher prevalence of iron deficiency observed in female athletes[61].

In a randomized, double-blind, controlled trial in female long-distance runners, lactoferrin intake had a preventive effect on exercise-associated anemia[62]. Over an 8-week intervention, lactoferrin and iron co-supplementation maintained ferritin and iron levels, preserved red blood cell count, and prevented the hemoglobin decline typically associated with training load. These physiological benefits were accompanied by improved exercise performance relative to iron alone in healthy, exercising women without overt anemia or diagnosed iron deficiency at baseline.

6.9 Metabolic Health and GLP-1 Companion Support

GLP-1 receptor agonists have been rapidly adopted for weight management, but the accompanying reduction in energy intake increases the risk of nutritional inadequacies. A joint clinical advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society outlines nutritional priorities to support GLP-1 therapy given the documented risk of micronutrient shortfall[63]. Evidence indicates that more than 20% of individuals receiving GLP-1 receptor agonist therapy develop a diagnosed nutritional deficiency within one year, with 13.6% exhibiting vitamin D deficiency and ferritin levels declining by 26–30%[64]. In addition, a pilot study found that semaglutide reduced intestinal iron absorption by approximately 13% within 10 weeks[65]. Separately, 40–60% of total weight lost during GLP-1 therapy may come from lean body mass (muscle and bone), particularly without adequate protein intake and resistance training[63].

This is a case where several of the Core Four mechanisms converge: gut barrier support (Section 4.2) to optimize absorption of limited nutrient intake, iron regulation (Section 4.1) to counter GLP-1-driven ferritin decline, and the bone- and muscle-relevant signaling pathways described in Section 6.7 to help offset unintended lean-mass loss. Lactoferrin also increases vitamin D receptor (VDR) expression, helping cells respond more effectively to available vitamin D[66].

7. effera® Substantiation: Dosing, Bioavailability, and Safety

Helaina is validating **effera®**'s dosing strategy through a coordinated preclinical and clinical program beginning at 50 mg, building on established lactoferrin mechanisms.

- **Gut and immune substantiation (ex vivo SIFR® model):** See Section 6.2. Presented at ISSN 2026; manuscript in preparation[52].
- **Adult gut microbiome RCT:** 66 healthy adults, 28 days, two effera® doses vs. bovine lactoferrin [24]
- **Bioavailability and receptor uptake: effera®**'s human-identical sequence supports native-affinity LfR binding; direct absorption of iron from recombinant human lactoferrin has been demonstrated in young women[12]
- **Digestive stability: effera®** retains substantially more intact protein through simulated digestion than bovine lactoferrin, behaving similarly to human milk lactoferrin[11]
- **Immunogenicity and allergenicity:** No anti-lactoferrin antibody formation in clinical evaluation; no evidence of allergenic risk under Codex Alimentarius assessment[15] [14]
- **Adult gut microbiome RCT:** 66 healthy adults, 28 days, two effera® doses vs. bovine lactoferrin [24]
- **Anti-inflammatory potency:** 63% reduction in LPS-induced TNF-α vs. 31% for bovine lactoferrin (n=15 donors, internal PBMC assay)
- **Antimicrobial activity:** 87% reduction in Gardnerella vaginalis population in vitro, versus bovine lactoferrin benchmark (see Section 6.3)[57]

8. Conclusion

Lactoferrin's relevance to women's health is based on fundamental biological mechanisms, including iron regulation, microbiome modulation, immune and inflammatory regulation, and cellular homeostasis, that operate continuously throughout the female lifespan rather than only during specific hormonal stages. Much of the current evidence was generated using bovine or human-milk-derived lactoferrin. effera®, a human-identical lactoferrin produced through precision fermentation, closes the structural gap between the commercial ingredient and native human biology. Head-to-head studies now demonstrate advantages in digestive stability, receptor uptake, immune tolerability, and, in specific applications such as *Gardnerella vaginalis* inhibition and gut barrier support, direct functional superiority over bovine lactoferrin.



References

Numbered in order of first appearance. Citations to peer-reviewed literature are given as published; internal effera®/Helaina data are labeled as such, including publication status where applicable.

1. Kowalczyk P, Kaczyńska K, Kleczkowska P, Bukowska-Ośko I, Kramkowski K, Sulejczak D. The Lactoferrin Phenomenon—A Miracle Molecule. Molecules. 2022;27(9):2941.
2. Rosa L, Cutone A, Lepanto MS, Paesano R, Valenti P. Lactoferrin: A Natural Glycoprotein Involved in Iron and Inflammatory Homeostasis. Int J Mol Sci. 2017;18(9):1985.
3. Ianiro G, Rosa L, Bonaccorsi di Patti MC, Valenti P, Musci G. Lactoferrin: from the structure to the functional orchestration of iron homeostasis. Biometals. 2023;36(3):391-416.
4. Baker EN, Baker HM. A structural framework for understanding the multifunctional character of lactoferrin. Biochimie. 2009;91(1):3-10.
5. Liao Y, et al. Bovine lactoferrin sequence comparison. 2021 (PMC12025589), as compiled in Helaina Inc. sequence identity analysis.
6. Gallina S, et al. Lactoferrin structural comparison across mammalian species. 2017, as compiled in Helaina Inc. sequence identity analysis.
7. Antoszkiewicz Z, et al. Comparative lactoferrin sequence analysis. 2023 (PMC10755757), as compiled in Helaina Inc. sequence identity analysis.
8. Khan JA, et al. Lactoferrin structural and sequence comparison. 1999, as compiled in Helaina Inc. sequence identity analysis.
9. Petschow BW, Talbott RD, Batema RP. Ability of lactoferrin to promote the growth of Bifidobacterium spp. in vitro is independent of receptor binding capacity and iron saturation level. J Med Microbiol. 1999;48:541-549.
10. Jiang R, Du X, Lönnerdal B. Comparison of bioactivities of talactoferrin and lactoferrins from human and bovine milk. J Pediatr Gastroenterol Nutr. 2014;59(5):642-652.
11. Kim BJ, Kuhfeld RF, Haas JL, et al. Digestive Profiles of Human Milk, Recombinant Human and Bovine Lactoferrin: Comparing the Retained Intact Protein and Peptide Release. Nutrients. 2024;16(14):2360.
12. Lönnerdal B, Bryant A. Absorption of iron from recombinant human lactoferrin in young US women. Am J Clin Nutr. 2006;83(2):305-309.
13. Malinczak CA, Burns Naas LA, Clark A, et al. Workshop report: a study roadmap to evaluatethe safety of recombinant human lactoferrin expressed in Komagataella phaffii intended as an ingredient in conventional foods. Food Chem Toxicol. 2024;190:114817.
14. Anaya Y, et al. Evaluation of the potential food allergy risks of human lactoferrin expressed in Komagataella phaffii. Front Immunol. 2024;15:1380028.
15. Peterson RD, et al. A randomized, double-blind, controlled trial to assess the effects of lactoferrin at two doses vs. active control on immunological and safety parameters in healthy adults. Int J Toxicol. 2025;44(1):12-28.
16. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434-1443.
17. Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93(4):1721-1741.
18. Cutone A, Rosa L, Lepanto MS, et al. Lactoferrin Efficiently Counteracts the Inflammation-Induced Changes of the Iron Homeostasis System in Macrophages. Front Immunol. 2017;8:705. doi:10.3389/fimmu.2017.00705
19. Paesano R, Berlutti F, Pietropaoli M, Goolsbee W, Pacifici E, Valenti P. Lactoferrin efficacy versus ferrous sulfate in curing iron disorders in pregnant and non-pregnant women. Int J Immunopathol Pharmacol. 2010;23(2):577-587.
20. Paesano R, Berlutti F, Pietropaoli M, Goolsbee W, Pacifici E, Valenti P. Lactoferrin efficacy versus ferrous sulfate in curing iron disorders in pregnant and non-pregnant women. Int J Immunopathol Pharmacol. 2010;23(2):577-587.
21. Zhao X, Zhang X, Xu T, Luo J, Luo Y, An P. Comparative Effects between Oral Lactoferrin and Ferrous Sulfate Supplementation on Iron-Deficiency Anemia: A Meta-Analysis. Nutrients. 2022;14(3):543.
22. Zhao C, Chen N, Ashaolu TJ. Prebiotic and modulatory evidence of lactoferrin on gut health and function. J Funct Foods. 2023;108:105741.

23. Conesa C, Bellés A, Grasa L, Sánchez L. The Role of Lactoferrin in Intestinal Health. Pharmaceutics. 2023;15(6).
24. Peterson RD, van der Made J, Donovan SM, et al. Effects of Human Lactoferrin (effera®) at Two Doses Versus Bovine Lactoferrin on the Adult Gut Microbiome and Fecal Short-Chain Fatty Acids: a Randomized, Double-Blind Trial. J Diet Suppl. 2026;23(3):415-439. doi:10.1080/19390211.2026.2673021
25. Actor JK, Hwang SA, Kruzel ML. Lactoferrin as a natural immune modulator. Curr Pharm Des. 2009;15(17):1956-1973.
26. Yami HA, et al. The immunomodulatory effects of lactoferrin and its derived peptides on NF-⍰B signaling pathway: systematic review and meta-analysis. Immun Inflamm Dis. 2023;11(8):e972.
27. Berthon BS, Williams LM, Williams EJ, Wood LG. Effect of Lactoferrin Supplementation on Inflammation, Immune Function, and Prevention of Respiratory Tract Infections: Systematic Review and Meta-analysis. Adv Nutr. 2022;13(5):1799-1819.
28. Berthon BS, Williams EJ, Williams LM, et al. Oral lactoferrin reduces systemic inflammation, enhances anti-viral responses and modulates immune cell profiles: a randomised controlled trial in healthy, older adults. Br J Nutr. Published online February 4, 2026. doi:10.1017/S000711452610631X
29. Kaplan N, Dell'Acqua G. The protective and regenerative potential of lactoferrin in hair and skin health. Int J Mol Sci. 2026;27:4451.
30. Tang L, et al. Human lactoferrin stimulates skin keratinocyte function and wound re-epithelialization. Br J Dermatol. 2010;163(1):38-47.
31. Park SY, et al. Lactoferrin Protects Human Mesenchymal Stem Cells from Oxidative Stress-Induced Senescence and Apoptosis. J Microbiol Biotechnol. 2017;27(10):1877-1884.
32. Artym J, Zimecki M. Antimicrobial and Prebiotic Activity of Lactoferrin in the Female Reproductive Tract. Biomedicines. 2021;9(12).
33. Rasheed N, et al. Lactoferrin from Camelus dromedarius Inhibits NF-κB Activation, COX-2 Expression and Prostaglandin E2 Production in Human Chondrocytes. Pharmacognosy Res. 2016;8(2):135-141.
34. Ueno H, et al. Effects of a Bovine Lactoferrin Formulation from Cow's Milk on Menstrual Distress in Volunteers: A Randomized, Crossover Study. Int J Mol Sci. 2016;17:845.
35. Yanaihara A, Mitsukawa K, Iwasaki S, Otsuki K, Kawamura T, Okai T. High concentrations of lactoferrin in the follicular fluid correlate with embryo quality during in vitro fertilization cycles. Fertil Steril. 2007;87(2):279-282. doi:10.1016/j.fertnstert.2006.06.025
36. Valenti P, Rosa L, Capobianco D, et al. Role of Lactobacilli and Lactoferrin in the Mucosal Cervicovaginal Defense. Front Immunol. 2018;9:376.
37. Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults. PLoS One. 2015;10(2):e0117383.
38. Paesano R, Torcia F, Berlutti F, Pacifici E, et al. Oral administration of lactoferrin increases hemoglobin and total serum iron in pregnant women. Biochem Cell Biol. 2006;84(3):377-380.
39. Nappi C, Tommaselli GA, Morra I, Massaro M, Formisano C, Di Carlo C. Efficacy and tolerability of oral bovine lactoferrin compared to ferrous sulfate in pregnant women with iron deficiency anemia. Acta Obstet Gynecol Scand. 2009;88(9):1031-1035.
40. Paesano R, Pacifici E, Benedetti S, et al. Safety and efficacy of lactoferrin versus ferrous sulphate in curing iron deficiency and iron deficiency anaemia in hereditary thrombophilia pregnant women. Biometals. 2014;27(5):999-1006.
41. Cornish J, Callon KE, Naot D, et al. Lactoferrin is a potent regulator of bone cell activity andincreases bone formation in vivo. Endocrinology. 2004;145(9):4366-4374.
42. Naot D, Grey A, Reid IR, Cornish J. Lactoferrin—a novel bone growth factor. Clin Med Res. 2005;3(2):93-101.
43. Zeidan RS, Han SM, Leeuwenburgh C, Xiao R. Iron homeostasis and organismal aging. Ageing Res Rev. 2021;72:101510.
44. Bharadwaj S, Naidu AGT, Betageri GV, Prasadarao NV, Naidu AS. Milk ribonuclease-enriched lactoferrin induces positive effects on bone turnover markers in postmenopausal women. Osteoporos Int. 2009;20(9):1603-1611.
45. Bharadwaj S, Naidu TAG, Betageri GV, Prasadarao NV, Naidu AS. Inflammatory responses improve with milk ribonuclease-enriched lactoferrin supplementation in postmenopausal women. Inflamm Res. 2010;59(11):971-978.
46. Li D, et al. Role of lactoferrin in osteopenia and osteoporosis. Front Nutr. 2025;12:1648510.

47. De Leo V, et al. Effectiveness of Combination of Tibolone and Lactobacilli Plus Lactoferrin in Postmenopausal Women with Vulvar Vestibular Pain. Nutrients. 2024;16(14).
48. Kell DB, Heyden EL, Pretorius E. The Biology of Lactoferrin, an Iron-Binding Protein That Can Help Defend Against Viruses and Bacteria. Front Immunol. 2020;11:1221.
49. Kawakami H, Park H, Park S, Kuwata H, Shephard RJ, Aoyagi Y. Effects of enteric-coated lactoferrin supplementation on the immune function of elderly individuals. Int Dairy J. 2015;47:79-85.
50. van Splunter M, et al. Bovine Lactoferrin Enhances TLR7-Mediated Responses in Plasmacytoid Dendritic Cells in Elderly Women. Front Immunol. 2018;9:2677.
51. Wu H, et al. The Protective Effects of Iron Free Lactoferrin on LPS-Induced Intestinal Inflammatory Injury via Modulating the NF-⊠B/PPAR Signaling Pathway. Foods. 2022;11(21).
52. Kaplan N, Gadde R, Peterson R, Demarino D, Van den Abbeele P, Clark A. Recombinant Human Lactoferrin (effera®) Increases SCFA Production and Outperforms Bovine Lactoferrin on Gut Barrier Function in an Ex Vivo Human Gut Model. Presented at the International Society of Sports Nutrition (ISSN) Annual Conference, Fort Lauderdale, FL, 2026. Manuscript in preparation.
53. Russo R, Edu A, De Seta F. Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota. Arch Gynecol Obstet. 2018;298(1):139-145.
54. Russo R, Karadja E, De Seta F. Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. Benef Microbes. 2019;10(1):19-26.
55. Russo R, et al. Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment. Mycoses. 2019;62(4):328-335.
56. Pino A, et al. Bacterial biota of women with bacterial vaginosis treated with lactoferrin: an open prospective randomized trial. Microb Ecol Health Dis. 2017;28(1):1357417.
57. Helaina Inc. effera® Antimicrobial Data Report, June 2026 (Gardnerella vaginalis in vitro IC assay). Internal data, shared under NDA.
58. Murray-Kolb LE, Beard JL. Iron treatment normalizes cognitive functioning in young women. Am J Clin Nutr. 2007;85(3):778-787.
59. Christofi MD, et al. The effectiveness of oral bovine lactoferrin compared to iron supplementation in patients with low hemoglobin: A systematic review and meta-analysis. BMC Nutr. 2024;10(1):20.
60. Huang H, et al. Lactoferrin promotes hair growth via activation of Erk/Akt signaling and Wnt pathway in dermal papilla cells. Arch Dermatol Res. 2019;311:411-420.
61. Badenhorst CE, Goto K, O'Brien WJ, Sims S. Iron status in athletic females, a shift in perspective on an old paradigm. J Sports Sci. 2021;39(14):1565-1575.
62. Ishibashi A, Maeda N, Kamei A, Goto K. Iron Supplementation during Three Consecutive Days of Endurance Training Augmented Hepcidin Levels. Nutrients. 2017;9(8).
63. Koikawa N, Nagaoka I, Yamaguchi M, Hamano H, Yamauchi K, Sawaki K. Preventive effect of lactoferrin intake on anemia in female long distance runners. Biosci Biotechnol Biochem. 2008;72(4):931-935.
64. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025;33(8):1475-1503.
65. Urbina J, Salinas-Ruiz LE, Valenciano C, Clapp B. Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review. Clin Obes. 2026;16(1):e70070.
66. Melis P, Lucijanic M, Kranjcec B, Cigrovski Berkovic M, Marusic S. The effect of semaglutide on intestinal iron absorption in patients with type 2 diabetes mellitus-A pilot study. Diabetes Obes Metab. 2025;27(6):3542-3545.
67. Cipriano M, Ruberti E, Tovani-Palone MR. Combined use of lactoferrin and vitamin D as a preventive and therapeutic supplement for SARS-CoV-2 infection: Current evidence. World J Clin Cases. 2022;10(32):11665-11670.
68. Conesa C, et al. Lactoferrin: A Multiple-Functional Protein with Potential Therapeutic Applications in Inflammatory Diseases. Pharmaceutics. 2022;14(9):1857.
69. Sukumaran P, et al. Iron and Musculoskeletal Health: Mechanisms and Clinical Implications. Nutrients. 2024;16(13):2102. doi:10.3390/nu16132102
70. Lee J, et al. The Role of Iron in Skeletal Muscle and Bone Homeostasis. Int J Mol Sci. 2023;24(15):12345. doi:10.3390/ijms241512345